Magnetic tool looks viable for retrieving stone fragments

Rendering stone fragments paramagnetic by exposure to iron oxide-based microparticles shows promise as a novel approach for reducing the number of small retained fragments after ureteroscopic lithotripsy, say researchers who are developing the technology.

Related Videos

TRT delivery: A urologist discusses options and patient preferences

Joseph Song, MD, describes his experience using the CVAC device

Experts assess pre-operative factors linked with buccal mucosa graft failure

Interim Results from ADVANCED 2

Integrating ctDNA in NMIBC: Promise and practical challenges

TARA-002 mechanism of action

Robert Jansen, MD, discusses evaluation of candidates for testosterone therapy

Ashley Winter, MD, discusses testosterone therapy for women

Vikram Narayan, MD, on embracing thoughtful tech adoption

Eating disorders and pelvic health: What clinicians need to know

Related Content

Advertisement

August 6th 2025

Pembrolizumab plus axitinib shows sustained benefit vs sunitinib in ccRCC

Hannah Clarke

Five-year data from the phase 3 KEYNOTE-426 trial confirm the clinical benefits of front-line pembrolizumab plus axitinib in advanced ccRCC.

August 6th 2025

Pearls & Perspectives: Tailoring BPH Therapies to the Patient, with Utsav Bansal, MD

Amy M. Pearlman, MD

Bansal unpacks how to personalize treatment plans in a therapeutic landscape now filled with minimally invasive and surgical options.

August 6th 2025

How to bill for mitomycin for intravesical solution in NMIBC

Jonathan Rubenstein, MD Mark Painter

"As with all medications and services, it is important to check with the patient’s insurer to determine their policy and whether the medication will be covered," write Jonathan Rubenstein, MD, and Mark Painter.

August 6th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

August 6th 2025

FDA updates in urology: July 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from July 2025.

August 6th 2025

SunRISe-1 data of TAR-200 in NMIBC published in Journal of Clinical Oncology

Hannah Clarke

Data show that TAR-200 monotherapy led to high complete response rates and encouraging DFS in patients with BCG-unresponsive high-risk NMIBC.

Related Content

Advertisement

August 6th 2025

Pembrolizumab plus axitinib shows sustained benefit vs sunitinib in ccRCC

Hannah Clarke

Five-year data from the phase 3 KEYNOTE-426 trial confirm the clinical benefits of front-line pembrolizumab plus axitinib in advanced ccRCC.

August 6th 2025

Pearls & Perspectives: Tailoring BPH Therapies to the Patient, with Utsav Bansal, MD

Amy M. Pearlman, MD

Bansal unpacks how to personalize treatment plans in a therapeutic landscape now filled with minimally invasive and surgical options.

August 6th 2025

How to bill for mitomycin for intravesical solution in NMIBC

Jonathan Rubenstein, MD Mark Painter

"As with all medications and services, it is important to check with the patient’s insurer to determine their policy and whether the medication will be covered," write Jonathan Rubenstein, MD, and Mark Painter.

August 6th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

August 6th 2025

FDA updates in urology: July 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from July 2025.

August 6th 2025

SunRISe-1 data of TAR-200 in NMIBC published in Journal of Clinical Oncology

Hannah Clarke

Data show that TAR-200 monotherapy led to high complete response rates and encouraging DFS in patients with BCG-unresponsive high-risk NMIBC.